[go: up one dir, main page]

DK3428274T3 - Anvendelse af nukleosominteragerende proteindomæner til forbedring af målrettet genommodifikation - Google Patents

Anvendelse af nukleosominteragerende proteindomæner til forbedring af målrettet genommodifikation Download PDF

Info

Publication number
DK3428274T3
DK3428274T3 DK18182999.5T DK18182999T DK3428274T3 DK 3428274 T3 DK3428274 T3 DK 3428274T3 DK 18182999 T DK18182999 T DK 18182999T DK 3428274 T3 DK3428274 T3 DK 3428274T3
Authority
DK
Denmark
Prior art keywords
nucleosominating
genomation
modification
protein domains
improve targeted
Prior art date
Application number
DK18182999.5T
Other languages
English (en)
Inventor
Fuqiang Chen
Xiao Ding
Yongmei Feng
Gregory D Davis
Original Assignee
Sigma Aldrich Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Aldrich Co Llc filed Critical Sigma Aldrich Co Llc
Application granted granted Critical
Publication of DK3428274T3 publication Critical patent/DK3428274T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102Mutagenizing nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/20Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/80Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK18182999.5T 2017-07-11 2018-07-11 Anvendelse af nukleosominteragerende proteindomæner til forbedring af målrettet genommodifikation DK3428274T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762531222P 2017-07-11 2017-07-11

Publications (1)

Publication Number Publication Date
DK3428274T3 true DK3428274T3 (da) 2021-11-15

Family

ID=62916578

Family Applications (2)

Application Number Title Priority Date Filing Date
DK18182999.5T DK3428274T3 (da) 2017-07-11 2018-07-11 Anvendelse af nukleosominteragerende proteindomæner til forbedring af målrettet genommodifikation
DK21193940.0T DK3988656T3 (da) 2017-07-11 2018-07-11 Anvendelse af nukleosom-interagerende proteindomæner til at forbedre målrettet genommodifikation

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK21193940.0T DK3988656T3 (da) 2017-07-11 2018-07-11 Anvendelse af nukleosom-interagerende proteindomæner til at forbedre målrettet genommodifikation

Country Status (17)

Country Link
US (3) US10604752B2 (da)
EP (2) EP3988656B9 (da)
JP (3) JP6994560B2 (da)
KR (3) KR102655021B1 (da)
CN (1) CN111183226A (da)
AU (3) AU2018299995B2 (da)
CA (1) CA3066790C (da)
DK (2) DK3428274T3 (da)
ES (2) ES2901629T3 (da)
FI (1) FI3988656T3 (da)
GB (3) GB2598847B (da)
IL (2) IL271197B2 (da)
LT (2) LT3428274T (da)
PL (2) PL3988656T3 (da)
PT (2) PT3988656T (da)
SG (1) SG11201911864PA (da)
WO (1) WO2019014230A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180250424A1 (en) 2014-10-10 2018-09-06 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US20190127713A1 (en) 2016-04-13 2019-05-02 Duke University Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
SG11201911864PA (en) 2017-07-11 2020-01-30 Sigma Aldrich Co Llc Using nucleosome interacting protein domains to enhance targeted genome modification
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
US10767193B2 (en) * 2018-02-15 2020-09-08 Sigma-Aldrich Co. Llc Engineered CAS9 systems for eukaryotic genome modification
WO2019204766A1 (en) 2018-04-19 2019-10-24 The Regents Of The University Of California Compositions and methods for gene editing
WO2020036653A2 (en) * 2018-04-25 2020-02-20 The Regents Of The University Of California Improved method for homology directed repair in cells
CA3102676A1 (en) 2018-06-04 2019-12-12 University Of Copenhagen Mutant cpf1 endonucleases
CA3104856A1 (en) 2018-06-29 2020-01-02 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
CN111718418B (zh) * 2019-03-19 2021-08-27 华东师范大学 一种增强基因编辑的融合蛋白及其应用
CN111718420B (zh) * 2019-03-19 2021-09-14 华东师范大学 一种用于基因治疗的融合蛋白及其应用
WO2020187272A1 (zh) * 2019-03-19 2020-09-24 上海邦耀生物科技有限公司 一种用于基因治疗的融合蛋白及其应用
SG11202111982UA (en) * 2019-05-13 2021-11-29 Emd Millipore Corp Synthetic self-replicating rna vectors encoding crispr proteins and uses thereof
US20230279373A1 (en) * 2019-09-09 2023-09-07 Beam Therapeutics Inc. Novel crispr enzymes, methods, systems and uses thereof
EP4127179A4 (en) * 2020-05-08 2025-07-23 Univ Duke CHROMATIN REMODELERS TO ENHANCE TARGETED GENE ACTIVATION
WO2021224506A1 (en) * 2020-05-08 2021-11-11 Universitat Pompeu Fabra Crispr-cas homology directed repair enhancer
WO2022059928A1 (ko) * 2020-09-21 2022-03-24 고려대학교 산학협력단 신규의 개량된 염기 편집 또는 교정용 융합단백질 및 이의 용도
EP4230737A4 (en) * 2020-09-21 2024-07-24 Korea University Research and Business Foundation NOVEL IMPROVED BASIC EDITING OR REVISION FUSION PROTEIN AND USE THEREOF
KR102699756B1 (ko) * 2020-09-24 2024-08-29 고려대학교 산학협력단 편집 효율이 향상된 프라임 편집 기반 유전자 교정용 조성물 및 이의 용도
AU2021374974A1 (en) * 2020-11-06 2023-05-25 Pairwise Plants Services, Inc. Compositions and methods for rna-encoded dna-replacement of alleles
CN114507689B (zh) * 2022-01-27 2024-01-16 山东大学 一种提高真核生物基因编辑效率的方法及其应用
CN115716880A (zh) * 2022-12-07 2023-02-28 云舟生物科技(广州)股份有限公司 一种核定位荧光蛋白及其应用
CN115948465B (zh) * 2022-12-16 2025-09-19 中国农业科学院北京畜牧兽医研究所 猪hat1基因修饰系统及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002360424A1 (en) 2001-11-26 2003-06-10 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
CA2522819A1 (en) 2003-04-22 2004-11-04 Immunomedics, Inc. Polyvalent protein complex
WO2013152220A2 (en) 2012-04-04 2013-10-10 Life Technologies Corporation Tal-effector assembly platform, customized services, kits and assays
EP3494997B1 (en) * 2012-07-25 2019-09-18 The Broad Institute, Inc. Inducible dna binding proteins and genome perturbation tools and applications thereof
KR102479178B1 (ko) 2012-12-06 2022-12-19 시그마-알드리치 컴퍼니., 엘엘씨 Crispr-기초된 유전체 변형과 조절
US20140273230A1 (en) 2013-03-15 2014-09-18 Sigma-Aldrich Co., Llc Crispr-based genome modification and regulation
KR102271292B1 (ko) * 2013-03-15 2021-07-02 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집의 특이성을 증가시키기 위한 rna-안내 foki 뉴클레아제(rfn)의 용도
WO2015048577A2 (en) 2013-09-27 2015-04-02 Editas Medicine, Inc. Crispr-related methods and compositions
US10570418B2 (en) 2014-09-02 2020-02-25 The Regents Of The University Of California Methods and compositions for RNA-directed target DNA modification
WO2016049251A1 (en) * 2014-09-24 2016-03-31 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
US20180250424A1 (en) 2014-10-10 2018-09-06 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
US10190106B2 (en) * 2014-12-22 2019-01-29 Univesity Of Massachusetts Cas9-DNA targeting unit chimeras
CA2968939A1 (en) 2014-12-24 2016-06-30 The Johns Hopkins University Systems and methods for genome modification and regulation
AU2016278226B2 (en) 2015-06-17 2021-08-12 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
WO2016210271A1 (en) 2015-06-24 2016-12-29 Sigma-Aldrich Co. Llc Cell cycle dependent genome regulation and modification
CN107922953B (zh) 2015-08-20 2022-03-04 应用干细胞有限公司 提高基因编辑效率的核酸酶
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
SG11201911864PA (en) 2017-07-11 2020-01-30 Sigma Aldrich Co Llc Using nucleosome interacting protein domains to enhance targeted genome modification

Also Published As

Publication number Publication date
AU2022200851A1 (en) 2022-03-03
IL309801B2 (en) 2024-12-01
CN111183226A (zh) 2020-05-19
SG11201911864PA (en) 2020-01-30
JP2022046532A (ja) 2022-03-23
KR102523217B1 (ko) 2023-04-20
CA3066790C (en) 2023-07-18
KR102655021B1 (ko) 2024-04-04
EP3988656A1 (en) 2022-04-27
PT3988656T (pt) 2024-11-07
GB202114520D0 (en) 2021-11-24
US20200208135A1 (en) 2020-07-02
JP7469285B2 (ja) 2024-04-16
EP3428274B1 (en) 2021-10-13
GB202103935D0 (en) 2021-05-05
US12065642B2 (en) 2024-08-20
IL309801B1 (en) 2024-08-01
IL271197B2 (en) 2024-06-01
AU2018299995A1 (en) 2020-01-02
KR20200021529A (ko) 2020-02-28
IL271197B1 (en) 2024-02-01
DK3988656T3 (da) 2024-11-11
IL271197A (en) 2020-01-30
GB201811358D0 (en) 2018-08-29
KR20240046316A (ko) 2024-04-08
GB2567917A (en) 2019-05-01
LT3428274T (lt) 2021-11-25
JP2020530287A (ja) 2020-10-22
AU2021245148B2 (en) 2024-01-04
GB2593814A (en) 2021-10-06
PT3428274T (pt) 2021-11-05
JP2024096783A (ja) 2024-07-17
BR112019028261A2 (pt) 2020-07-14
IL309801A (en) 2024-02-01
JP6994560B2 (ja) 2022-02-21
ES2997490T3 (en) 2025-02-17
AU2021245148A1 (en) 2021-11-04
EP3988656B9 (en) 2024-11-27
CA3066790A1 (en) 2019-01-17
AU2022200851B2 (en) 2023-12-14
US20210024916A1 (en) 2021-01-28
WO2019014230A1 (en) 2019-01-17
GB2567917B (en) 2021-05-12
GB2598847A (en) 2022-03-16
LT3988656T (lt) 2024-11-11
GB2598847B (en) 2022-06-01
ES2901629T3 (es) 2022-03-23
PL3428274T3 (pl) 2022-01-03
EP3428274A1 (en) 2019-01-16
US12221606B2 (en) 2025-02-11
GB2593814B (en) 2022-01-05
AU2018299995B2 (en) 2021-10-28
US10604752B2 (en) 2020-03-31
FI3988656T3 (fi) 2024-10-29
PL3988656T3 (pl) 2024-12-16
KR20230053732A (ko) 2023-04-21
US20190017042A1 (en) 2019-01-17
EP3988656B1 (en) 2024-09-18

Similar Documents

Publication Publication Date Title
DK3428274T3 (da) Anvendelse af nukleosominteragerende proteindomæner til forbedring af målrettet genommodifikation
IL290809A (en) Tau-protein targeting protacs and associated methods of use
IL286888A (en) Use of pridopidine to treat depression or anxiety
DK3604527T3 (da) Anvendelse af programmerbare dna-bindingsproteiner til at forbedre målrettet genommodifikation
EP3678681A4 (en) INTERLEUKIN-18 VARIANTS AND THEIR PROCEDURES FOR USE
IL256079A (en) Humanized and affinity matured antibodies to fcrh5 and methods of use
PL3353210T3 (pl) Przeciwciała anty-TIGIT i sposoby stosowania
DK3515478T3 (da) Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
PT3250610T (pt) Anticorpos de fcrn e métodos de utilização dos mesmos
EP3377059A4 (en) INHIBITORS OF CXCR2
EA201691974A1 (ru) Антитела против ox40 и способы их применения
ME03335B (me) Konstrukti uspa2 proteina i njihove upotrebe
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
IL269540A (en) Purification of phycobiliproteins
IL268731A (en) New uses of anti-sirpg antibodies
EP3314503A4 (en) SIMULATION OF AN APPLICATION
PL3565828T3 (pl) Białko fuzyjne SIRP1 ALFA-41BBL i sposoby jego zastosowania
EP3578165A4 (en) IRREGULARITY CORRECTION COSMETIC PRODUCT
DK3259349T3 (da) Dehydrogenase-katalyseret fremstilling af FDCA
IL272851A (en) Methods of using dipivefrin
DK3099800T3 (da) Ekspression og oprensning af crm197 og beslægtede proteiner
DK3166628T3 (da) Terapeutisk anvendelse af knoglemorfogenetiske proteiner
EP3602547C0 (en) TARGET SAMPLE GENERATION
IL283136A (en) Antibodies to mucin-16 and methods of use thereof
EP3630046C0 (en) ANTI-DOUBLECORTIN-LIKE KINASE 1 ANTIBODIES AND METHODS OF USE THEREOF